HealthTop Headlines

COVID-19 Vaccine: Pune Firm Gets Nod For Human Trial of Covishield, 1,600 People to Participate

It aims at mass-producing the vaccine, which will be priced below Rs 1,000.

New Delhi: The expert panel which was looking into Serum Institute of India’s proposal to conduct the second and the third phases of the human clinical trial of the Oxford vaccine candidate has asked the country’s drug controller to allow Serum Institute of India to proceed.

Pune’s Serum Institute of India is the world’s largest vaccine maker by the number of doses produced and sold. It has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca.

It aims at mass-producing the vaccine, which will be priced below Rs 1,000.

The initial proposal submitted by the Pune firm came under scrutiny and the expert committee suggested a few revisions.

The SII had submitted a revised proposal on Wednesday after the expert panel on Tuesday, following deliberations over its application, had asked it to revise its protocol for the trials besides seeking some additional information.

“An urgent meeting was held by the subject expert committee on COVID-19 on Friday to consider SII’s application. Following deliberation, it has recommended that permission be granted for phase 2 and 3 human clinical trials of the potential vaccine developed by the Oxford University – Covishield,” an official source said.


Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button